PCJ Stock Chart & Stats
€5.47
€0.00(0.00%)
At close: 4:00 PM EDT
€5.47
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.56 - €6.28
Previous CloseN/A
Volume0.00
Average Volume (3M)76.00
Market Cap
€317.28M
Enterprise Value€108.56
Total Cash (Recent Filing)€168.27M
Total Debt (Recent Filing)€23.17M
Price to Earnings (P/E)5.0
Beta1.07
Next Earnings
Aug 13, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.28
Shares Outstanding56,995,144
10 Day Avg. Volume30
30 Day Avg. Volume76
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.75
Price to Sales (P/S)47.95
P/FCF Ratio-3.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.13Price Target Upside213.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.66
Revenue Forecast (FY)€58.09M
Bulls Say, Bears Say
Bulls Say
Early Commercial Revenue TractionSustained product receipts from commercial patients indicate initial product-market fit and reproducible commercialization capability. Recurring commercial revenue reduces binary clinical risk, supports incremental scaling of manufacturing and field teams, and creates a foundation for durable top-line growth as QTCs and referral networks expand.
Broad Payer CoverageHigh published coverage materially lowers reimbursement risk for a specialty gene therapy and improves expected cash realization per treated patient. A 95% commercial coverage footprint and an anticipated favorable payer mix support predictable revenue conversion as volumes scale and reduce long-term access barriers relative to therapies lacking payer acceptance.
Manageable Leverage And Stronger Balance SheetLow leverage provides financial flexibility for a clinical-stage biotech, lowering near-term solvency risk and enabling continued investment in commercialization and pipeline work without immediate distress. Expanded assets and equity improve capacity to raise capital or structure partnerships while preserving optionality for strategic transactions.
Bears Say
Heavy Operating Cash BurnPersistent and large negative operating cash flow forces reliance on external financing, which can dilute shareholders or raise cost of capital. Cash losses outpace early product revenue, compress runway and limit the firm's ability to self-fund further commercialization or clinical milestones unless burn meaningfully declines or new funding is secured.
Sustained Operating Losses And Earnings QualityLarge operating losses and a disparity between positive net income and negative operating cash flow indicate earnings are influenced by non‑operational items and not yet reflective of sustainable profitability. High SG&A and a cost base tied to commercialization mean revenue must scale substantially to achieve durable operating breakeven.
Operational Scaling And Payer Timing RisksComplex QTC onboarding, variable biopsy lead times and lengthy insurance approvals create structural friction to scaling throughput. These multi-month, center-level delays widen the path to steady-state revenue per center, increase unit customer acquisition costs, and make cash flow and margin improvement timing unpredictable over the medium term.
Abeona Therapeutics News
PCJ FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Abeona Therapeutics lowest stock price was €3.56 and its highest was €6.28 in the past 12 months.
What is Abeona Therapeutics’s market cap?
Abeona Therapeutics’s market cap is €317.28M.
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is Aug 13, 2026 which is in 6 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on May 13, 2026. The company reported -€0.26 earnings per share for the quarter, beating the consensus estimate of -€0.29 by €0.03.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics does not currently pay dividends.
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -0.2.
How many shares outstanding does Abeona Therapeutics have?
Abeona Therapeutics has 56,995,144 shares outstanding.
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of -€0.26 in its last earnings report, beating expectations of -€0.29. Following the earnings report the stock price went down -2.861%.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Currently, no hedge funds are holding shares in DE:PCJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abeona Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€17.13 (213.16% Upside)
€17.13 (213.16% Upside)
Blogger Sentiment
Bullish
DE:PCJ Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €1.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
99.76%
Trailing 12-Months
Company Description
Abeona Therapeutics
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
PCJ Company Deck
PCJ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents clear early commercial momentum for ZEVASKYN (notable revenue acceleration, 95% published commercial coverage, growing QTC network and manufacturing success with no harvest failures) and meaningful pipeline advancement with the in-licensed PSMA SIR-T program. Offsetting these positives are elevated operating expenses (notably SG&A), a larger reported net loss driven partly by a $7M upfront license payment, a declining cash balance, and operational / payer timing risks (variable biopsy lead times and lengthy insurance approvals for out-of-state Medicaid). On balance, the positives — strong initial revenue growth, payer coverage, successful manufacturing outcomes and a targeted oncology asset with limited near-term spend — outweigh the near-term financial and operational challenges.View all DE:PCJ earnings summariesPCJ Stock 12 Month Forecast
Average Price Target
€17.13
▲(213.16% Upside)